Compare FCBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | NGNE |
|---|---|---|
| Founded | 1874 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.5M | 744.9M |
| IPO Year | 1996 | 2014 |
| Metric | FCBC | NGNE |
|---|---|---|
| Price | $48.36 | $34.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 77.6K | ★ 310.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | $75.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.21 | $15.93 |
| 52 Week High | $47.50 | $43.66 |
| Indicator | FCBC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 71.10 | 47.61 |
| Support Level | $41.51 | $18.24 |
| Resistance Level | N/A | $37.27 |
| Average True Range (ATR) | 1.29 | 3.04 |
| MACD | 0.34 | -0.65 |
| Stochastic Oscillator | 93.90 | 17.67 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.